External broker reports(aggregated public sources), HDFC Securities

HDFC Securities

External broker reports(aggregated public sources)

HDFC securities is the best online trading platform for stocks, IPOs, mutual fund in India. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

Thematic (Sector/Industry)

<ul><li>DLF: DLF reported a stable quarter with pre-sales of INR 20.3bn (+39.1%/-83.2% YoY/QoQ), largely on the back of sustenance sales from recently-launched Dahilas</li><li>Collections improved significantly, led by robust bookings, to INR 33.2bn (+50.6%/+6.5% YoY/QoQ)</li><li>Moreover, it is heading towards the launch of the Mumbai project, along with Privana North in Q1FY26, following its next uber luxury project DLF 5 at the end of this fiscal, which should further improve margins</li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

DLF: DLF reported a stable quarter with pre-sales of INR 20.3bn (+39.1%/-83.2% YoY/QoQ), largely on the back of sustenance sales from recently-launched DahilasCollections improved significantly, led by robust bookings, to INR 33.2bn (+50.6%/+6.5% YoY/QoQ)Moreover, it is heading towards the launch of the Mumbai project, along with Privana North in Q1FY26, following its next uber luxury project DLF 5 at the end of this fiscal, which should further improve marginsContent is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

HSIE Results Daily: DLF, Torrent Pharma, Dixon Technologies, Zydus Lifesciences...

<ul><li>IRB Infra: IRB Infrastructure Developers Limited (IRB) reported revenue/EBITDA/APAT of INR 17.8/7.4/60bn, beat/(miss) to our estimates of 5.9/-4.24/159% respectively</li><li>The order book (OB) as of Dec’24 stood at INR 315bn, with EPC contributing 10% (INR 32bn) and O&amp;M contributing 90% (INR 283bn)</li><li>Moreover, in the long term, the company is expecting opportunities under the PPP mode for BOT projects worth INR 2trn</li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

IRB Infra: IRB Infrastructure Developers Limited (IRB) reported revenue/EBITDA/APAT of INR 17.8/7.4/60bn, beat/(miss) to our estimates of 5.9/-4.24/159% respectivelyThe order book (OB) as of Dec’24 stood at INR 315bn, with EPC contributing 10% (INR 32bn) and O&amp;M contributing 90% (INR 283bn)Moreover, in the long term, the company is expecting opportunities under the PPP mode for BOT projects worth INR 2trnContent is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

HSIE Results Daily: IRB Infra, Relaxo Footwears

<ul><li>Larsen &amp; Toubro: Larsen &amp; Toubro (LT) reported revenue/EBITDA/APAT at INR 615.5/63.6/33.9bn, a beat/(miss) of 6.3/0.6/1.5%</li><li>P&amp;M margins came in at 7.6% (+20bps YoY), and LT expects to maintain a positive YoY margin expansion trend in ensuing quarters and retained 8.2-8.25% guidance for FY25</li><li>Despite Q2FY25 being impacted by heavy monsoon, LT reported strong 20.6% YoY revenue growth and maintained 15/10% revenue/order inflow guidance for FY25</li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Larsen &amp; Toubro: Larsen &amp; Toubro (LT) reported revenue/EBITDA/APAT at INR 615.5/63.6/33.9bn, a beat/(miss) of 6.3/0.6/1.5%P&amp;M margins came in at 7.6% (+20bps YoY), and LT expects to maintain a positive YoY margin expansion trend in ensuing quarters and retained 8.2-8.25% guidance for FY25Despite Q2FY25 being impacted by heavy monsoon, LT reported strong 20.6% YoY revenue growth and maintained 15/10% revenue/order inflow guidance for FY25Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

HSIE Results Daily: Larsen & Toubro, Prestige Estates, Voltas, Kaynes Technology

External broker reports(aggregated public sources), Motilal Oswal Financial Services Limited

Motilal Oswal

Motilal Oswal Financial Services Limited

Motilal Oswal Financial Services Limited is an Indian diversified financial services firm offering a range of financial products and services. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

Equity Bottom-Up

IRB Infrastructure Developers / Equity Bottom-Up

<ul><li>Motilal Oswal's research report onIRB Infrastructure IRB Infrastructure (IRB)’s revenue grew 27% YoY to INR20.6b in 4QFY24 (in line).</li><li>EBITDA margin came in at 43.2% (down 370bp YoY, below our estimate of 45%).</li><li>EBITDA grew 17% YoY to INR8.9b, in line with our estimate.</li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Motilal Oswal's research report onIRB Infrastructure IRB Infrastructure (IRB)’s revenue grew 27% YoY to INR20.6b in 4QFY24 (in line).EBITDA margin came in at 43.2% (down 370bp YoY, below our estimate of 45%).EBITDA grew 17% YoY to INR8.9b, in line with our estimate.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

IRB Infrastructure - In-Line Performance; Order Pipeline Remains Robust

<ul><li>Dr Reddy’s Laboratories: EBITDA grew (14% YoY) as +13% YoY sales growth (-3% QoQ US, +5% YoY in EU, +9% YoY EMs, and +34% YoY in RoW, India declined 12% YoY, adjusted growth was at 11%), steady gross margin (+65 bps YoY) and muted staff cost were offset by higher R&amp;D/SG&amp;A (+28/+22% YoY)</li><li>DRRD expects to sustain growth in the US over the next few years with steady traction in gRevlimid and new launches (20+ launches p.a for the next few years)</li><li>The company expects India to see steady growth in FY25, led by new launches, scale-up in key therapies, and in-licensing opportunities</li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Dr Reddy’s Laboratories: EBITDA grew (14% YoY) as +13% YoY sales growth (-3% QoQ US, +5% YoY in EU, +9% YoY EMs, and +34% YoY in RoW, India declined 12% YoY, adjusted growth was at 11%), steady gross margin (+65 bps YoY) and muted staff cost were offset by higher R&amp;D/SG&amp;A (+28/+22% YoY)DRRD expects to sustain growth in the US over the next few years with steady traction in gRevlimid and new launches (20+ launches p.a for the next few years)The company expects India to see steady growth in FY25, led by new launches, scale-up in key therapies, and in-licensing opportunitiesContent is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

HSIE Results Daily: Dr Reddy’s Laboratories, Lupin, IRB Infra, Max Financial

India

IRB Infrastructure Developers Limited is an infrastructure development and construction company in India with significant experience in the roads and highways sector.  The Company is also involved in the real estate development sector.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

IRB Infrastructure Developers (IRB IN)

HSIE Results Daily: DLF, Torrent Pharma, Dixon Technologies, Zydus Lifesciences...

DLF reported a stable quarter with pre-sales of INR 20.3bn (+39.1%/-83.2% YoY/QoQ), largely on the back of sustenance sales from recently-launched...

HDFC Securities

HSIE Results Daily: IRB Infra, Relaxo Footwears

IRB Infrastructure Developers Limited (IRB) reported revenue/EBITDA/APAT of INR 17.8/7.4/60bn, beat/(miss) to our estimates of 5.9/-4.24/159%...

HDFC Securities

HSIE Results Daily: Larsen & Toubro, Prestige Estates, Voltas, Kaynes Technology

Larsen & Toubro: Larsen & Toubro (LT) reported revenue/EBITDA/APAT at INR 615.5/63.6/33.9bn, a beat/(miss) of 6.3/0.6/1.5%

HDFC Securities

IRB Infrastructure - In-Line Performance; Order Pipeline Remains Robust

Motilal Oswal's research report onIRB Infrastructure IRB Infrastructure (IRB)’s revenue grew 27% YoY to INR20.6b in 4QFY24 (in line).

Motilal Oswal

HSIE Results Daily: Dr Reddy’s Laboratories, Lupin, IRB Infra, Max Financial

DRRD expects to sustain growth in the US over the next few years with steady traction in gRevlimid and new launches (20+ launches p.a for the next...

HDFC Securities

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)